Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcino

2018 ◽  
Vol 25 (6) ◽  
pp. 603-604 ◽  
Author(s):  
Jun Teishima ◽  
Akio Matsubara
Keyword(s):  
Editorial Comment ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Alanine Transaminase ◽  
Prognostic Impact ◽  
Aspartate Transaminase ◽  
First Line ◽  
Tyrosine Kinase Inhibitor Therapy

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy

Respiration ◽  
2017 ◽  
Vol 95 (3) ◽  
pp. 169-176 ◽  
Author(s):  
Diego Kauffmann-Guerrero ◽  
Rudolf Maria Huber ◽  
Simone Reu ◽  
Amanda Tufman ◽  
Pontus Mertsch ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Egfr Mutations ◽  
First Line ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Nsclc Patients
Sign in / Sign up

Export Citation Format

Share Document